Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) Net Margin (2022 - 2025)

Historic Net Margin for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to 13.38%.

  • Indivior Pharmaceuticals' Net Margin rose 62100.0% to 13.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.93%, marking a year-over-year increase of 63700.0%. This contributed to the annual value of 0.59% for FY2024, which is 121200.0% up from last year.
  • Per Indivior Pharmaceuticals' latest filing, its Net Margin stood at 13.38% for Q3 2025, which was up 62100.0% from 5.96% recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Net Margin ranged from a high of 30.8% in Q2 2023 and a low of 136.51% during Q4 2022
  • Moreover, its 4-year median value for Net Margin was 15.71% (2025), whereas its average is 2.68%.
  • The largest annual percentage gain for Indivior Pharmaceuticals' Net Margin in the last 5 years was 1597200bps (2023), contrasted with its biggest fall of -1126400bps (2023).
  • Indivior Pharmaceuticals' Net Margin (Quarter) stood at 136.51% in 2022, then skyrocketed by 117bps to 23.21% in 2023, then crashed by -70bps to 7.05% in 2024, then soared by 90bps to 13.38% in 2025.
  • Its Net Margin was 13.38% in Q3 2025, compared to 5.96% in Q2 2025 and 18.05% in Q1 2025.